Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells $302,325.17 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 3,143 shares of the stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $96.19, for a total value of $302,325.17. Following the sale, the chief operating officer owned 23,286 shares of the company’s stock, valued at $2,239,880.34. This represents a 11.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Peter Radovich also recently made the following trade(s):

• On Thursday, January 22nd, Peter Radovich sold 2,382 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.33, for a total transaction of $222,312.06.

Mirum Pharmaceuticals Trading Up 2.4%

NASDAQ:MIRM traded up $2.35 during midday trading on Tuesday, hitting $99.27. 679,931 shares of the company traded hands, compared to its average volume of 877,176. The firm’s fifty day moving average is $77.82 and its 200-day moving average is $71.21. The firm has a market capitalization of $5.10 billion, a P/E ratio of -115.43 and a beta of 0.48. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals, Inc. has a 12-month low of $36.88 and a 12-month high of $99.44.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. During the same quarter in the previous year, the firm posted ($0.30) EPS. The firm’s revenue was up 47.1% compared to the same quarter last year. On average, sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Comerica Bank increased its holdings in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares in the last quarter. AQR Capital Management LLC grew its holdings in Mirum Pharmaceuticals by 307.3% in the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after acquiring an additional 37,028 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Mirum Pharmaceuticals by 7.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after acquiring an additional 1,720 shares in the last quarter. Caxton Associates LLP purchased a new position in shares of Mirum Pharmaceuticals in the 1st quarter worth about $217,000. Finally, Empowered Funds LLC raised its position in Mirum Pharmaceuticals by 15.4% in the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after buying an additional 5,120 shares during the last quarter.

More Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Large director purchase — Director Patrick J. Heron bought 131,425 shares at ~$68.48 (Jan 23), increasing his ownership ~40%, signaling strong insider conviction. SEC Filing – Heron Form 4
• Positive Sentiment: Price-target upgrade / bullish analyst note — HC Wainwright raised its price target to $130 and kept a Buy rating, issuing a very bullish long‑range EPS view (FY2030 EPS est. $6.16). That upgrade and forecast materially boosts upside expectations. The Fly – HC Wainwright Upgrade
• Positive Sentiment: Acquisition closed — Mirum completed the acquisition of Bluejay Therapeutics, expanding its rare‑disease portfolio and reinforcing growth/synergy narratives that investors favor in biotech M&A. Yahoo Finance – Bluejay Acquisition
• Positive Sentiment: Momentum / new 52‑week high after upgrades — The stock hit a fresh 52‑week high following analyst upgrades and the above news, reinforcing momentum trading and positive sentiment among investors. American Banking News – 52‑Week High
• Negative Sentiment: Executive selling — Several senior executives sold shares on Jan 26 (CEO Christopher Peetz sold 6,831 shares; COO Peter Radovich, CFO Eric Bjerkholt, SVP Jolanda Howe also sold smaller amounts). While transactions appear modest relative to market cap and include routine diversification, they can trigger short‑term selling pressure or worry some investors. SEC filings: CEO CEO Form 4, COO COO Form 4, CFO CFO Form 4, SVP SVP Form 4. Also summarized in a media note on insider selling: American Banking News – Insider Selling

Wall Street Analyst Weigh In

Several research analysts recently issued reports on MIRM shares. JMP Securities set a $95.00 price objective on Mirum Pharmaceuticals in a research report on Wednesday, November 5th. Raymond James Financial reiterated a “strong-buy” rating and set a $110.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Evercore ISI restated an “outperform” rating and issued a $101.00 target price on shares of Mirum Pharmaceuticals in a research note on Tuesday, January 20th. Stifel Nicolaus increased their price target on Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Finally, Morgan Stanley lifted their target price on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $104.92.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.